113181-02-5

Basic information

• Product Name: (2S)-3-BroMo-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-Methyl-propanaMide
• Synonyms: (2S)-3-BroMo-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-Methyl-propanaMide
• CAS NO: 113181-02-5
• Molecular Formula: C₁₂H₁₀BrF₃N₂O₂
• Molecular Weight: 351.1192096
• Product Categories: Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 113181-02-5.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Acetone (Slightly), Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (2S)-3-BroMo-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-Methyl-propanaMide(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-3-BroMo-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-Methyl-propanaMide(113181-02-5)
• EPA Substance Registry System: (2S)-3-BroMo-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-Methyl-propanaMide(113181-02-5)

Safety Data

• Hazardous Substances Data: 113181-02-5(Hazardous Substances Data)

Usage

Description

(2S)-3-Bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-propanamide is a complex organic compound characterized by its unique molecular structure and chemical properties. It is a yellow solid with a specific configuration at the chiral center, denoted by the (2S) designation. (2S)-3-BroMo-N-[4-cyano-3-(trifluoroMethyl)phenyl]-2-hydroxy-2-Methyl-propanaMide is known for its reactivity and is utilized in the synthesis of various chemical entities, particularly in the field of pharmaceuticals and biochemistry.

Uses

1. Used in Pharmaceutical Synthesis:
(2S)-3-Bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-propanamide is used as a reactant for the preparation of hydroxy(phenylthio)propionanilides. These compounds serve as affinity ligands for the androstane receptor, which plays a crucial role in the development and function of the reproductive, nervous, and urinary systems. The androstane receptor is a target for various therapeutic applications, including the treatment of hormone-related disorders and certain cancers.
2. Used in Chemical Research:
As a complex organic molecule with unique structural features, (2S)-3-Bromo-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-propanamide is also employed in chemical research. It can be used to study the effects of different functional groups on the reactivity and stability of molecules, as well as to explore new synthetic pathways and methodologies in organic chemistry.
3. Used in the Synthesis of Biochemical Compounds:
The compound's unique structure and reactivity make it a valuable building block in the synthesis of various biochemical compounds. It can be used to create new molecules with potential applications in the fields of biochemistry and molecular biology, such as enzyme inhibitors, receptor agonists or antagonists, and other bioactive molecules.

Upstream product

• 1010729-05-1 C₄H₆BrClO₂ 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 927203-28-9 3-bromomethyl-3-methyl-tetrahydro-pyrrolo[2,1-c][1,4]oxazine-1,4-dione 
• 106089-20-7 (S)-(-)-3-bromo-2-hydroxy-2-methylpropanoic acid 

Downstream Products

• 2031161-35-8 (2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(5-fluoro-1H-indol-1-yl)-2-hydroxy-2-methylpropanamide 
• 1019972-88-3 (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyloxirane-2-carboxamide 
• 1132656-73-5 (R)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 
• 261904-44-3 N₁-[4-cyano-3-(trifluoromethyl)phenyl]-(2S)-3-[(4-aminophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide 

Relevant articles and documents

Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer

We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-Antagonists that exert broad-scope AR antagonism. Pharmacological ev

Synthetic method of alpha-hydroxypropanamide derivatives with optical activity

The invention discloses a synthetic method of alpha-hydroxypropanamide derivatives with optical activity and belongs to the field of organic synthesis. Proline taken as a chiral auxiliary, as well asmethacryloyl chloride, is subjected to acylation, bromination and chiral auxiliary removal, a product and 4-cyano-3-trifluoromethylaniline are subjected to nucleophilic substitution, and 3-bromo-2-hydroxy-2-methyl-N-[(4-cyano-3-trifluoromethyl)phenyl]propanamide is obtained and subjected to nucleophilic substitution with 4-cyanophenol, and the compound 3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethylphenyl]-2-hydroxy-2-methylpropanamide with optical activity is prepared. 3-bromo-2-hydroxy-2-methyl propionic acid and 4-nitro-3-trifluoromethylaniline are subjected to aminolysis, a product is subjected to nucleophilic substitution with paracetamol, and the compound 3-(4-acetoxyphenoxy)-N-[4-nitro-3-(trifluoromethylphenyl]-2-hydroxy-2-methylpropanamide with optical activity is prepared. The efficient synthetic method of the alpha-hydroxypropanamide derivatives with optical activity is provided.

SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.